Cargando…

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment

HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for the treatment of HER2 positive metastatic bre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Shengnan, Liu, Qian, Han, Xinwei, Qin, Shuang, Zhao, Weiheng, Li, Anping, Wu, Kongming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704598/ https://www.ncbi.nlm.nih.gov/pubmed/29209558 http://dx.doi.org/10.1186/s40164-017-0091-4

Ejemplares similares

Recent advances of bispecific antibodies in solid tumors
por: Yu, Shengnan, et al.
Publicado: (2017)

A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
por: Yu, Shengnan, et al.
Publicado: (2019)

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
por: Dalla Palma, Benedetta, et al.
Publicado: (2020)

The application of mathematical modelling to the design of bispecific monoclonal antibodies
por: van Steeg, Tamara J., et al.
Publicado: (2016)

DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis
por: Liu, Qian, et al.
Publicado: (2018)

Correction: DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis
por: Liu, Qian, et al.
Publicado: (2022)

EGFR-TKIs resistance via EGFR-independent signaling pathways
por: Liu, Qian, et al.
Publicado: (2018)

The role of neoantigen in immune checkpoint blockade therapy
por: Yi, Ming, et al.
Publicado: (2018)

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
por: Qin, Shuang, et al.
Publicado: (2019)

The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
por: Yi, Ming, et al.
Publicado: (2021)

Bispecific Antibodies: From Research to Clinical Application
por: Ma, Jiabing, et al.
Publicado: (2021)

Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy.
por: Bosslet, K., et al.
Publicado: (1991)

Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody
por: Huang, Sijia, et al.
Publicado: (2018)

Bispecific antibodies and their applications
por: Fan, Gaowei, et al.
Publicado: (2015)

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2018)

Recent advances and challenges of bispecific antibodies in solid tumors
por: Wu, Yuze, et al.
Publicado: (2021)

Gut microbiome modulates efficacy of immune checkpoint inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

Chimeric antigen receptor T cells: a novel therapy for solid tumors
por: Yu, Shengnan, et al.
Publicado: (2017)

Characterisation of a humanised bispecific monoclonal antibody for cancer therapy.
por: Bruynck, A., et al.
Publicado: (1993)

Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine
por: Xu, Hanxiao, et al.
Publicado: (2018)

Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma
por: Atallah-Yunes, Suheil Albert, et al.
Publicado: (2022)

Bispecific Antibodies for Diagnostic Applications
por: Parashar, Archana, et al.
Publicado: (2011)

A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects In Vitro and In Vivo
por: Mohammadi, Mehdi, et al.
Publicado: (2021)

Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds
por: Malm, Magdalena, et al.
Publicado: (2016)

The development of bispecific antibodies and their applications in tumor immune escape
por: Zhang, Xiaolong, et al.
Publicado: (2017)

Therapeutic Effect of Ansamitocin Targeted to Tumor by a Bispecific Monoclonal Antibody
por: Okamoto, Kayoko, et al.
Publicado: (1992)

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
por: Yi, Ming, et al.
Publicado: (2019)

Identifying Tumorigenesis and Prognosis-Related Genes of Lung Adenocarcinoma: Based on Weighted Gene Coexpression Network Analysis
por: Yi, Ming, et al.
Publicado: (2020)

Understanding the structure–property relationship of bispecific monoclonal antibodies with Fc site-specific substitutions
por: Zhao, Bo, et al.
Publicado: (2023)

Application of (89)Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ß monoclonal antibody
por: Stergiou, N., et al.
Publicado: (2023)

Autophagy Facilitates the Development of Breast Cancer Resistance to the Anti-HER2 Monoclonal Antibody Trastuzumab
por: Vazquez-Martin, Alejandro, et al.
Publicado: (2009)

A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3
por: Rau, Alexander, et al.
Publicado: (2021)

HER2/PD1 bispecific antibody in IgG4 subclass with superior anti‐tumour activities
por: Chu, Wendi, et al.
Publicado: (2022)

Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma
por: Tateyama, Nami, et al.
Publicado: (2022)

Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
por: Niu, Mengke, et al.
Publicado: (2023)

In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody.
por: Negri, D. R., et al.
Publicado: (1995)

CXCL1 as an Unfavorable Prognosis Factor Negatively Regulated by DACH1 in Non-small Cell Lung Cancer
por: Yu, Shengnan, et al.
Publicado: (2020)

YEAST SURFACE DISPLAY OF FULL-LENGTH IGG FOR ENGINEERING MONOCLONAL AND BISPECIFIC ANTIBODIES
por: Jiang, Youwei
Publicado: (2023)

Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene
Publicado: (1992)

Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer
por: Lum, Lawrence G., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_trf97n0m11qnasi5bk4m96dm2a